|
Characteristics
|
No. of patients
|
Person-years
|
No. with TB
|
TB IDR [95% CI]
|
Pvalue*
|
|---|
|
Total patients
|
11,631
|
45,698
|
170
|
0.37 [0.32-0.43]
| |
|
Gender
| | | | |
0.04
|
|
Female
|
2,283
|
9,153
|
45
|
0.49 [0.37-0.66]
| |
|
Male
|
9,347
|
36,536
|
125
|
0.34 [0.29-0.41]
| |
|
Median age, years
| | | | |
0.41 (NS)
|
|
≤38
|
5,773
|
23,250
|
91
|
0.39 [0.32-0.48]
| |
|
>38
|
5,838
|
22,387
|
78
|
0.35 [0.28-0.43]
| |
|
Region of origin
| | | | |
<0.001
|
|
Germany
|
8,344
|
33,449
|
71
|
0.21 [0.17-0.27]
| |
|
Sub-Sahara Africa
|
1,298
|
4,871
|
59
|
1.20 [0.94-1.56]
| |
|
Other countries
|
1,789
|
6,710
|
34
|
0.52 [0.38-0.71]
| |
|
HIV-transmission risk group category
| | | | |
<0.001
|
|
MSM
|
6,093
|
24,189
|
53
|
0.22 [0.17-0.28]
| |
|
HPC
|
1,528
|
5,910
|
69
|
1.17 [0.92-1.48]
| |
|
PWID
|
943
|
3,534
|
14
|
0.42 [0.23-0.67]
| |
|
Others†
|
1,846
|
7,768
|
22
|
0.28 [0.18-0.43]
| |
|
CD4+ blood cell count (cells/μl)
| | | | |
<0.001
|
|
>350
|
5,037
|
19,702
|
44
|
0.22 [0.17-0.30]
| |
|
200–350
|
2,459
|
9,893
|
37
|
0.36 [0.26-0.50]
| |
|
<200
|
3,580
|
14,111
|
82
|
0.58 [0.47-0.72]
| |
|
Viral load (log10 copies/ml)
| | | | |
<0.001
|
|
<5
|
7,583
|
30,137
|
92
|
0.31 [0.25-0.37]
| |
|
≥5
|
3,162
|
12,490
|
65
|
0.52 [0.41-0.66]
| |
|
Antiretroviral therapy
| | | | |
<0.001
|
|
Never started cART
|
2,424
|
4,801
|
59
|
1.23 [0.95-1.59]
| |
|
cART during follow-up
|
9,207
|
40,897
|
111
|
0.27 [0.23-0.33]
| |
|
Follow-up
| | | | |
<0.001
|
|
First year
|
2,421
|
10,174
|
109
|
1.07 [0.89-1.29]
| |
|
Second year
|
1,615
|
8,248
|
16
|
0.19 [0.12-0.32]
| |
- TB, tuberculosis; IDR, incidence density rate (cases per 100 person-years); CI, confidence interval; NS, non-significant; MSM, men who have sex with men; HPC, high HIV-prevalence countries; PWID, person who inject drugs; cART, combination antiretroviral therapy.
- *Obtained by χ2 test for difference in TB IDR.
-
†Others included heterosexual, blood transfusion and mother to child transmission.
